Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
It's interesting what we can read on the internet.
the investment world is very informative.
And I say it again: 2015 will be a great year.
At least for NNVC and its shareholders.
Just sayin
FN
That is the stock market game.
Up and Down
Well said DrKaz.
Merry Christmas Weedie.
Merry Christmas .
FN
Agreed!
Why you don't patse the full comment:
Earlier today (Dec. 22), Blumenthal visited NanoViricides’ lab in Shelton to view the facility and discuss the progress of the Ebola drug. After a detailed tour of the facility that lasted a little less than an hour, Blumenthal praised company founder Dr. Anil Diwan and his team. “I’m very impressed by the potential of this cutting edge technology,” he said. However, Blumenthal cautioned that because it is cutting edge there is a potential that the treatment might not work, and emphasized the fact that his and his office’s push to get the drug tested was not proof of its effectiveness.
“As you can appreciate we are not scientists, we can’t evaluate the scientific merits of the work,” he told reporters,“but we think it deserves to be evaluated and considered for support by the Pentagon because the threat of Ebola is so desperately urgent and immediate to so many people.”
]Before he left the NanoViricides facility he joked, “I’d rather bet on them than the casino.”
Another Connecticut company, Protein Sciences in Meriden, is working on developing an Ebola vaccine. However, if the NanoViricide drug works it can be used to treat those already infected with the virus, as well as prophylactically. If the drug proves successful in its initial tests it could skip clinical trials and be sent to regions of Africa heavily infected by the virus, as has happened with other experimental Ebola drugs. Samuel Brauer, a consultant for NanoViricides, says even if everything goes smoothly with the testing the timeline for when the drug could be sent to Africa is not clear, but it would likely be a matter of “months not years.”
See our original story below below for the detailed history of NanoViricides, Inc. and the science behind the company’s proposed Ebola drug.
Where did you read that?
Article & Pictures of Blumenthal visit (Link)
http://www.connecticutmag.com/Blog/Connecticut-Today/August-2014/Anti-Ebola-Drug-Under-Development-by-Connecticut-Company/
NanoViricides : West Haven company opens Shelton lab in hopes of Ebola cure
12/22/2014 | 10:33pm US/Eastern
Dec. 23--SHELTON -- A company that is developing new anti-viral drugs hopes it will have a cure for Ebola, which is still in the research phase, put on the fast track for development in the fight against the disease.
NanoViricides, whose headquarters are on Wood Street in West Haven, opened its research and development lab at 1 Controls Drive in July. The company, with a net worth of $250 million, employs more than 20 and expects to double that in the next two years.
U.S. Sen. Richard Blumenthal, D-Conn., toured the newly renovated plant on Monday.
Blumenthal is helping the company have its research evaluated by the U.S. Army Medical Research Institute of Infectious Diseases and, once a drug is developed, to move into clinical trials on an emergency basis.
AMRIID evaluates "different approaches to cures for various kind of diseases and they focus very intently on Ebola," Blumenthal said. "We have expedited their attention on the work being done here."
The company is operating without government financing now, but, Meeta Vyas, chief financial officer, said if the Ebola drug were successful, "we would apply for a Department of Defense grant."
NanoViricides is developing potential cures for the flu and HIV as well as Ebola. The flu drug is 18 months from clinical trials, said Anil Diwan, president and chairman, but if an Ebola drug looks promising it would go into trials more quickly because of the emergency in west Africa.
"Once the data from AMRIID comes out, we'll discuss it with them and then we'll decide the next step," Diwan said. "It could be as early as March 15."
The Shelton lab will enable NanoViricides to ramp up its research and to manufacture the drug if it's found to succeed against Ebola.
According to the Centers for Disease Control and Prevention, there have been 19,340 cases in Guinea, Sierra Leone and Liberia as of Dec. 20, plus seven in Mali, a new site for the disease. There have been 7,524 confirmed deaths in those four countries, the CDC reported.
Protein Sciences of Meriden, among other companies, is working on an Ebola vaccine. Diwan said NanoViricides, which he launched in 1992, is researching "a completely novel new mechanism. We are defining a new class of drugs."
If it works, it can be taken not only by people with Ebola but also by others, such as healthcare workers, to prevent contracting the disease.
Diwan described the drug's action: "We try to replicate how the virus binds to the cell," so that the ebolavirus is tricked into binding onto the drug instead of the living cell.
"In competition against the cell surface, our stuff wins," Diwan said.
Call Ed Stannard at 203-680-9382. Do you have questions, feedback or ideas about our news coverage? Connect with New Haven Register editors at AskTheRegister.com
Is it your cat?
$40?
in the pocket.
It's interesting what we can read on the internet.
the investment world is very informative.
And I say it again: 2015 will be a great year.
At least for NNVC and its shareholders.
Just sayin
FN
Oh don't worry, 2015 is going to be a great year.
At least for NNVC.
The stock will be at $20.
Sorry!
The stock will be at $20
Sorry!
Your post should unswear many questions.
Great job!
FN
Very informative!
Thanks leif.
FN
Let's not forget that we should get some results with FluCide that we already know has been 100% successful in the pass.
We have 2 different drugs.
Worst case scenario FluCide will be the winner.
Best case scenario EbolaCide2 and FluCide are successful.
Then it's Time for MersCide.
How high do you think the stock will be at the end of 2015?
Heavens is very high !
For serious investors.
The negatives will be fried when they will see NNVC succeeding!
Easy to understand
FN
Year whatever
Happy new year.
Merry Christmas !
This is a $100 stock.
It will go back up.
Azna
Davdid care more about his wallet than us .
He get excited when the stock goes down.
Agreed.
Believe.
Yep! Act on it!
It will never come at that price.
This is a great opportunity.
FN